BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL
5777 results:

  • 1. The Father of Wisdom: "The Influence of Surgical Experience on Overall Survival in Patients with Malignant Gliomas".
    Florian IS; Beni L; Andrasoni Z; Aldea C; Florian IA
    Adv Tech Stand Neurosurg; 2024; 49():181-200. PubMed ID: 38700685
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Decoding dynamic interactions between EGFR-TKD and DAC through computational and experimental approaches: A novel breakthrough in lung melanoma treatment.
    Meher RK; Mir SA; Singh K; Mukerjee N; Nayak B; Kumer A; Zughaibi TA; Khan MS; Tabrez S
    J Cell Mol Med; 2024 May; 28(9):e18263. PubMed ID: 38685671
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. A qualitative evaluation of factors influencing tumor Treating fields (TTFields) therapy decision making among brain tumor patients and physicians.
    Kumthekar P; Lyleroehr M; Lacson L; Lukas RV; Dixit K; Stupp R; Kruser T; Raizer J; Hou A; Sachdev S; Schwartz M; Pa JB; Lezon R; Schmidt K; Amidei C; Kaiser K
    BMC Cancer; 2024 Apr; 24(1):527. PubMed ID: 38664630
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Demographic bias in misdiagnosis by computational pathology models.
    Vaidya A; Chen RJ; Williamson DFK; Song AH; Jaume G; Yang Y; Hartvigsen T; Dyer EC; Lu MY; Lipkova J; Shaban M; Chen TY; Mahmood F
    Nat Med; 2024 Apr; 30(4):1174-1190. PubMed ID: 38641744
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Travel burdens to access care among children with cancer between 2016 and 2019: Analysis of a national population-based cancer registry in Japan.
    Tsutsui A; Murakami Y; Okamura S; Fujimaki T; Endo M; Ohno Y
    PLoS One; 2024; 19(4):e0300840. PubMed ID: 38625911
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. In Silico Transcriptomic Expression of MSR1 in Solid tumors Is Associated with Responses to Anti-PD1 and Anti-CTLA4 Therapies.
    Sanvicente A; Díaz-Tejeiro C; Nieto-Jiménez C; Paniagua-Herranz L; López Cade I; Balázs G; Moreno V; Pérez-Segura P; Calvo E; Ocaña A
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612803
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Exploring Regorafenib Responsiveness and Uncovering Molecular Mechanisms in Recurrent Glioblastoma tumors through Longitudinal In Vitro Sampling.
    Morelli M; Lessi F; Franceschi S; Ferri G; Giacomarra M; Menicagli M; Gambacciani C; Pieri F; Pasqualetti F; Montemurro N; Aretini P; Santonocito OS; Di Stefano AL; Mazzanti CM
    Cells; 2024 Mar; 13(6):. PubMed ID: 38534332
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. De novo missense variants in exon 9 of SEPHS1 cause a neurodevelopmental condition with developmental delay, poor growth, hypotonia, and dysmorphic features.
    Mullegama SV; Kiernan KA; Torti E; Pavlovsky E; Tilton N; Sekula A; Gao H; Alaimo JT; Engleman K; Rush ET; Blocker K; Dipple KM; Fettig VM; Hare H; Glass I; Grange DK; Griffin M; Phornphutkul C; Massingham L; Mehta L; Miller DE; Thies J; Merritt JL; Muller E; Osmond M; Sawyer SL; Slaugh R; Hickey RE; Wolf B; ; ; Choudhary S; Simonović M; Zhang Y; Palculict TB; Telegrafi A; Carere DA; Wentzensen IM; Morrow MM; Monaghan KG; Yang J; Juusola J
    Am J Hum Genet; 2024 Apr; 111(4):778-790. PubMed ID: 38531365
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. NPS-2143 inhibit glioma progression by suppressing autophagy through mediating AKT-mTOR pathway.
    Nie JL; Li Q; Yin HT; Yang JH; Li M; Li Q; Fan XH; Zhao QQ; Wen ZP
    J Cell Mol Med; 2024 Apr; 28(7):e18221. PubMed ID: 38509759
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Stereotactic radiotherapy for head and neck paragangliomas: How long should we wait for treatment response?
    Yazici G; Kahvecioglu A; Yuce Sari S; Ozyigit G; Yildiz D; Cengiz M
    Radiother Oncol; 2024 Jun; 195():110232. PubMed ID: 38499272
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Neurological autoimmunity in patients with non-pulmonary neuroendocrine neoplasms: clinical manifestations and neural autoantibody profiles.
    Mangioris G; Halfdanarson TR; Lennon VA; Chang BK; Dubey D; Dyck PJB; Flanagan EP; McKeon A; Mills JR; Pittock SJ; Zekeridou A
    Eur J Neurol; 2024 Jun; 31(6):e16273. PubMed ID: 38466015
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Recurrence Patterns and Surveillance Imaging in Pediatric Brain tumor Survivors.
    Cacciotti C; Lenzen A; Self C; Pillay-Smiley N
    J Pediatr Hematol Oncol; 2024 Apr; 46(3):e227-e232. PubMed ID: 38447113
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Comparison of the oncolytic activity of a replication-competent and a replication-deficient herpes simplex virus 1.
    Lindner G; Walter A; Magnus CL; Rosenhammer K; Holoborodko B; Koch V; Hirsch S; Grossmann L; Li S; Knipe DM; DeLuca N; Schuler-Thurner B; Gross S; Schwertner B; Toelge M; Rohrhofer A; Stöckl S; Bauer RJ; Knoll G; Ehrenschwender M; Haferkamp S; Schmidt B; Schuster P
    Immunology; 2024 Jun; 172(2):279-294. PubMed ID: 38444199
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy.
    Yadav S; Lawhn-Heath C; Paciorek A; Lindsay S; Mirro R; Bergsland EK; Hope TA
    J Nucl Med; 2024 Mar; 65(3):409-415. PubMed ID: 38428966
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study.
    Eigler C; McDougall L; Bauman A; Bernhardt P; Hentschel M; Blackham KA; Nicolas G; Fani M; Wild D; Cordier D
    J Nucl Med; 2024 Apr; 65(4):573-579. PubMed ID: 38423782
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Assessment of Social Vulnerabilities of Care and Prognosis in Adult Ocular Melanomas in the US.
    Mensah JA; Fei-Zhang DJ; Rossen JL; Rahmani B; Bentrem DJ; Stein JD; French DD
    Ann Surg Oncol; 2024 May; 31(5):3302-3313. PubMed ID: 38418655
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Hand2 Immunohistochemistry in the Diagnosis of Paragangliomas and Other Neuroendocrine Neoplasms.
    Soukup J; Manethova M; Stejskal V; Novakova M; Duskova J; Hornychova H; Hacova M; Staniczkova-Zambo I; Zelinka T; Kosak M; Cesak T; Netuka D; Ryska A; Gabalec F
    Endocr Pathol; 2024 Mar; 35(1):14-24. PubMed ID: 38416360
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma.
    Hu P; Dai HI; Bourdage J; Zhou D; Trang K; Kowalski K; Bello C; Hibma J; Khandelwal A; Cowan K; Dong J; Venkatakrishnan K; Gao W
    Clin Transl Sci; 2024 Mar; 17(3):e13730. PubMed ID: 38411318
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro.
    Cao Q; Hajosch A; Kast RE; Loehmann C; Hlavac M; Fischer-Posovszky P; Strobel H; Westhoff MA; Siegelin MD; Wirtz CR; Halatsch ME; Karpel-Massler G
    Br J Cancer; 2024 May; 130(8):1365-1376. PubMed ID: 38396172
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial.
    Bol KF; Schreibelt G; Bloemendal M; van Willigen WW; Hins-de Bree S; de Goede AL; de Boer AJ; Bos KJH; Duiveman-de Boer T; Olde Nordkamp MAM; van Oorschot TGM; Popelier CJ; Pots JM; Scharenborg NM; van de Rakt MWMM; de Ruiter V; van Meeteren WS; van Rossum MM; Croockewit SJ; Koeneman BJ; Creemers JHA; Wortel IMN; Angerer C; Brüning M; Petry K; Dzionek A; van der Veldt AA; van Grünhagen DJ; Werner JEM; Bonenkamp JJ; Haanen JBAG; Boers-Sonderen MJ; Koornstra RHT; Boomsma MF; Aarntzen EHJ; Gotthardt M; Nagarajah J; de Witte TJM; Figdor CG; de Wilt JHW; Textor J; de Groot JWB; Gerritsen WR; de Vries IJM
    Nat Commun; 2024 Feb; 15(1):1632. PubMed ID: 38395969
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 289.